Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Bought by Smith Group Asset Management LLC

Smith Group Asset Management LLC increased its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 25.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,824 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,774 shares during the period. Smith Group Asset Management LLC’s holdings in Collegium Pharmaceutical were worth $727,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Caxton Associates LP acquired a new stake in shares of Collegium Pharmaceutical in the 1st quarter worth about $1,730,000. Foundry Partners LLC acquired a new stake in shares of Collegium Pharmaceutical in the 2nd quarter worth about $492,000. LSV Asset Management increased its holdings in shares of Collegium Pharmaceutical by 188.7% in the 1st quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock worth $14,773,000 after acquiring an additional 248,751 shares during the period. O Shaughnessy Asset Management LLC increased its stake in Collegium Pharmaceutical by 159.3% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 45,735 shares of the specialty pharmaceutical company’s stock valued at $1,775,000 after buying an additional 28,100 shares during the period. Finally, Vanguard Group Inc. increased its stake in Collegium Pharmaceutical by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock valued at $90,479,000 after buying an additional 17,942 shares during the period.

Collegium Pharmaceutical Trading Up 1.2 %

NASDAQ COLL opened at $35.13 on Tuesday. The firm’s 50 day moving average price is $37.66 and its two-hundred day moving average price is $35.30. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.04 and a current ratio of 1.11. Collegium Pharmaceutical, Inc. has a twelve month low of $21.11 and a twelve month high of $42.29. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of 14.64 and a beta of 0.94.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.22. The business had revenue of $145.28 million for the quarter, compared to the consensus estimate of $143.94 million. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. Collegium Pharmaceutical’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period in the prior year, the business posted $1.13 earnings per share. Equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.79 EPS for the current year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $36.62, for a total value of $351,295.66. Following the completion of the sale, the executive vice president now directly owns 53,816 shares of the company’s stock, valued at $1,970,741.92. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, EVP Shirley R. Kuhlmann sold 19,248 shares of the business’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the sale, the executive vice president now directly owns 120,161 shares in the company, valued at approximately $4,602,166.30. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Thomas B. Smith sold 9,593 shares of the business’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the sale, the executive vice president now owns 53,816 shares of the company’s stock, valued at $1,970,741.92. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 3.98% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on COLL. Truist Financial raised their target price on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Needham & Company LLC reissued a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. HC Wainwright raised their target price on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, September 5th. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd. Finally, Piper Sandler restated a “neutral” rating and set a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $42.60.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.